Karuna Could Submit Schizophrenia Drug to FDA by Mid-Year
Business
Karuna Could Submit Schizophrenia Drug to FDA by Mid-Year
2023-03-20 20:55:40
by Dan McCue

BOSTON — Encouraged by positive topline results from its phase 3 trial for its new therapy for adults with schizophrenia, Karuna Therapeutics announced Monday that it is on track to submit KarXT to the Food and Drug Administration for approval... Read More

Straight From The Well
scroll top